The role of technological innovations in health care has increased over the past years and will continue to improve the diagnosis, monitoring, and treatment of various physical and mental disorders. In biobehavioral and psychosomatic medicine, the use of technology has also increased in both research and clinical contexts. The articles in the current special issue of Psychosomatic Medicine focus on technological solutions that have been applied to patient-monitoring/assessment (health-related behaviors and vital functioning) and treatment (ehealth and mhealth interventions). Although such solutions are promising and considered acceptable by patients and health care providers, important barriers have also been identified regarding the implementation of these technological advances. Topics addressed in this issue cover the following themes: the use of biological and behavioral sensors that are linked to user smartphones, technological innovations in clinical conditions (asthma, alcohol-associated liver disease, and chronic pain), the use of virtual humans in clinical settings, digital mental health interventions, and the importance of reducing health disparities in the development and implementation of technological innovation. These topics are critically relevant to the field of biobehavioral and psychosomatic medicine and provide future directions for research and clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PSY.0000000000001240 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Baseline characteristics and 2-year functional outcome data of patients undergoing an arthroscopic rotator cuff repair in Switzerland, results of the ARCR_Pred study.
PLoS One
January 2025
Orthopaedic Surgery and Traumatology, University Hospital Basel, Basel, Switzerland.
The ARCR_Pred study was initiated to document and predict the safety and effectiveness of arthroscopic rotator cuff repair (ARCR) in a representative Swiss patient cohort. In the present manuscript, we aimed to describe the overall and baseline characteristics of the study, report on functional outcome data and explore case-mix adjustment and differences between public and private hospitals. Between June 2020 and November 2021, primary ARCR patients were prospectively enrolled in a multicenter cohort across 18 Swiss and one German orthopedic center.
View Article and Find Full Text PDFDeciphering the psychological tapestry of FGIDs: unveiling the impact of negative affect, rumination, and expression suppression.
BMC Public Health
January 2025
School of Psychology, Guizhou Normal University, Guizhou, China.
Background: Functional Gastrointestinal Disorders (FGIDs) constitute a group of psychosomatic diseases characterized primarily by disruptions in the functioning of the digestive system, profoundly impacting the lives of affected individuals.
Objective: This study aims to investigate the influence of negative affect (NA) on the gastrointestinal symptoms of FGID patients, as well as the mediating role of rumination and the regulatory effects of expression suppression (ES) as an emotional regulation strategy.
Methods: A survey was conducted on 1000 patients (403M, 597F) with gastrointestinal disorders at a tertiary hospital using the negative affect subscale from the DS-14 (Type D Personality Scale), the Gastrointestinal Symptom Rating Scale (GSRS), the Rumination Response Scale (RRS), and the expression suppression subscale from the Gross-John Emotion Regulation Strategy.
Utilization of telemedicine in conjunction with wearable devices for patients with chronic musculoskeletal pain: a randomized controlled clinical trial.
Sci Rep
January 2025
Faculty of Health Science, Osaka Yukioka College of Health Science, Ibaraki, Osaka, Japan.
The present randomized controlled trial aimed to investigate the effects of home-based telemedicine with wearable devices and usual care on pain-related outcomes in patients with chronic musculoskeletal pain, compared to usual care alone. The patients with chronic musculoskeletal pain were randomly allocated to the usual care group or the telemedicine group, which participated in telemedicine with wearable devices, the objective data from which were recorded, in conjunction with usual care for six months. The primary outcome measure was the Numeric Rating Scale (NRS) for pain.
View Article and Find Full Text PDFEmpagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study.
Sci Rep
January 2025
Endocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, P.O. Box: 13145-784, Tehran, Iran.
The management of Type-2 Diabetes Mellitus (T2DM) remains challenging in cases of poor glycemic control despite triple Oral Hypoglycemic Agent (OHA) therapy. This prospective cohort study aimed to assess the effectiveness of Empagliflozin as part of a quadruple OHA regimen over a 7-year follow-up period in 575 adult patients with uncontrolled T2DM on a triple OHA regimen and who were unwilling to initiate insulin therapy. Overall, 92.
View Article and Find Full Text PDFDeterminants of perceived patient benefit in a longitudinal cohort study of patients with psoriasis and atopic dermatitis.
Sci Rep
January 2025
Department of Psychotherapy and Psychosomatic Medicine, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany.
The Dermatology Life Quality Index (DLQI) should be used to assess treatment success in psoriasis (PSO). However, the DLQI does not assess the importance and achievement of treatment goals. The Patient Benefit Index (PBI) is a questionnaire that takes both into account.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!